Search

Your search keyword '"Jean-Michel Bouler"' showing total 3 results
Start Over Author "Jean-Michel Bouler" Journal drug discovery today
3 results on '"Jean-Michel Bouler"'

1. Therapeutic strategies for treating osteolytic bone metastases

Author

Jean-Claude Scimeca, Hugues Pascal-Mousselard, Heidy Schmid-Antomarchi, Jean-Michel Bouler, Annie Schmid-Alliana, Elise Verron, Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation (CEISAM), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'ingénierie osteo-articulaire et dentaire (LIOAD), and Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Oncology, Osteolysis, medicine.medical_treatment, Disease, 0302 clinical medicine, Quality of life, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], Drug Discovery, Medicine, MESH: Animals, 0303 health sciences, Bone Density Conservation Agents, Localized Cancer, Prognosis, MESH: Bone Neoplasms, 3. Good health, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 030220 oncology & carcinogenesis, Systemic administration, MESH: Life Expectancy, medicine.medical_specialty, Antineoplastic Agents, Bone Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Bone resorption, MESH: Bone Density Conservation Agents, 03 medical and health sciences, Life Expectancy, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Internal medicine, Animals, Humans, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], [SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/Biomaterials, 030304 developmental biology, Pharmacology, MESH: Humans, business.industry, MESH: Quality of Life, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, medicine.disease, Surgery, Radiation therapy, Quality of Life, MESH: Antineoplastic Agents, MESH: Osteolysis, business
Abstract

International audience; The recent progress in oncologic management of patients with localized cancer or metastatic disease has permitted a significant improvement in life expectancy. Nevertheless, bone metastases and their consequent skeletal-related events (SREs) are still associated with unfavorable prognosis and greatly affect quality of life. Global management of these bone metastases includes traditional local approaches (surgery, radiotherapy, etc.) and systemic administration of chemotherapeutic agents. This review focuses on treatments specific for bone metastases and, in particular, on inhibitors of bone resorption that are effective for preventing and delaying the development of SREs.

Published
2014
Full Text
View/download PDF

2. Gallium as a potential candidate for treatment of osteoporosis

Author

Jean-Michel Bouler, Jean-Claude Scimeca, E. Verron, Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation (CEISAM), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Laboratoire d'ingénierie osteo-articulaire et dentaire (LIOAD), and Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
media_common.quotation_subject, Osteoporosis, Osteoclasts, chemistry.chemical_element, Potential candidate, Gallium, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pharmacology, Bone tissue, Malignancy, MESH: Bone Density Conservation Agents, 03 medical and health sciences, 0302 clinical medicine, MESH: Osteoclasts, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], Drug Discovery, medicine, Animals, Humans, MESH: Animals, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], [SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/Biomaterials, Internalization, 030304 developmental biology, media_common, 0303 health sciences, MESH: Humans, Bone Density Conservation Agents, business.industry, MESH: Gallium, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, medicine.disease, 3. Good health, Clinical trial, medicine.anatomical_structure, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, chemistry, 030220 oncology & carcinogenesis, Cancer research, business, MESH: Osteoporosis
Abstract

International audience; Gallium (Ga) is a semi-metallic element that displays antitumor, antiresorptive, anti-inflammatory and immunosuppressive properties. Among all these properties, antitumor properties were the most extensively applied and have shown efficacy in treatment of Paget's disease, myeloma and hypercalcemia in cases of malignancy. By contrast, no clinical trials have been conducted in prevention and/or treatment of osteoporosis. In this article I focus on Ga effects on bone tissue and cells, as well as on molecular mechanisms governing Ga internalization into cells. Eventually, the potential of Ga as an antiosteoporotic agent is discussed.

Published
2012
Full Text
View/download PDF

3. Calcium phosphate biomaterials as bone drug delivery systems: a review

Author

Elise Verron, Jean-Michel Bouler, Ibrahim Khairoun, Jérôme Guicheux, Regenerative Medicine and Skeleton research lab (RMeS), Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation (CEISAM), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Laboratoire d'ingénierie osteo-articulaire et dentaire (LIOAD), and Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Calcium Phosphates, Drug Compounding, chemistry.chemical_element, Nanotechnology, 02 engineering and technology, Calcium, Bone and Bones, 03 medical and health sciences, chemistry.chemical_compound, Drug Delivery Systems, Pharmaceutical technology, In vivo, Drug Discovery, Animals, Humans, [SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/Biomaterials, 030304 developmental biology, Pharmacology, 0303 health sciences, Drug Carriers, Chemistry, business.industry, Biomaterial, 021001 nanoscience & nanotechnology, Phosphate, Biotechnology, Delayed-Action Preparations, Drug delivery, 0210 nano-technology, business, Drug carrier
Abstract

A short review is proposed on the existing literature for the research performed in calcium phosphate (CaP) biomaterials used as drug delivery systems. In the first part, a brief update is given on the performance of both CaP ceramics and CaP cements. Second, a review of the research and clinical situation is developed for CaP materials already used as drug delivery systems. Experimental works performed for local delivery are reported. In particular, a description is given of the in vitro and in vivo studies in which these materials are loaded with various proteins and drugs.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results